JP2010065037A5 - - Google Patents

Info

Publication number
JP2010065037A5
JP2010065037A5 JP2009233816A JP2009233816A JP2010065037A5 JP 2010065037 A5 JP2010065037 A5 JP 2010065037A5 JP 2009233816 A JP2009233816 A JP 2009233816A JP 2009233816 A JP2009233816 A JP 2009233816A JP 2010065037 A5 JP2010065037 A5 JP 2010065037A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
sequence
apo
ligand
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009233816A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010065037A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2010065037A publication Critical patent/JP2010065037A/ja
Publication of JP2010065037A5 publication Critical patent/JP2010065037A5/ja
Pending legal-status Critical Current

Links

JP2009233816A 2002-06-24 2009-10-07 Apo−2リガンド/trail変異体とその使用法 Pending JP2010065037A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39105002P 2002-06-24 2002-06-24

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2004516142A Division JP4574350B2 (ja) 2002-06-24 2003-06-23 Apo−2リガンド/trail変異体とその使用法

Publications (2)

Publication Number Publication Date
JP2010065037A JP2010065037A (ja) 2010-03-25
JP2010065037A5 true JP2010065037A5 (enExample) 2010-12-09

Family

ID=30000661

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2004516142A Expired - Lifetime JP4574350B2 (ja) 2002-06-24 2003-06-23 Apo−2リガンド/trail変異体とその使用法
JP2009233816A Pending JP2010065037A (ja) 2002-06-24 2009-10-07 Apo−2リガンド/trail変異体とその使用法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2004516142A Expired - Lifetime JP4574350B2 (ja) 2002-06-24 2003-06-23 Apo−2リガンド/trail変異体とその使用法

Country Status (7)

Country Link
US (4) US20060141561A1 (enExample)
EP (2) EP2500032A1 (enExample)
JP (2) JP4574350B2 (enExample)
AU (2) AU2003247609A1 (enExample)
CA (1) CA2489348A1 (enExample)
IL (1) IL165777A0 (enExample)
WO (1) WO2004001009A2 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2461292A1 (en) * 2001-10-02 2003-04-10 Genentech, Inc. Apo-2 ligand variants and uses thereof
GB0328261D0 (en) * 2003-12-05 2004-01-07 Univ Groningen Improved cytokine design
SG151294A1 (en) 2004-03-23 2009-04-30 Biogen Idec Inc Receptor coupling agents and therapeutic uses thereof
RU2007112929A (ru) * 2004-09-08 2008-10-20 Дженентек, Инк. (Us) Способы применения лигандов рецептора смерти и антител к cd20
GB0524316D0 (en) * 2005-11-29 2006-01-04 Medical Res Council Tumour necrosis factor-related apoptosis-inducing ligands (TRAILs)
KR100886783B1 (ko) 2006-06-12 2009-03-04 성균관대학교산학협력단 N-말단이 수식된 peg-trail 결합체, 이의 제조방법 및 이의 용도
US8008261B2 (en) * 2006-08-04 2011-08-30 Mayo Foundation For Medical Education And Research Methods of reducing trail-induced apoptosis by trail isoforms
WO2009040811A2 (en) 2007-09-24 2009-04-02 Bar-Ilan University Polymer nanoparticles coated by magnetic metal oxide and uses thereof
MX2010004374A (es) * 2007-10-31 2010-04-30 Medimmune Llc Armazones proteinicos.
WO2011079293A1 (en) * 2009-12-23 2011-06-30 Ambrx, Inc Tumor necrosis factor-related apoptosis inducing ligand polypeptides and their uses
ES2755398T3 (es) 2010-04-13 2020-04-22 Medimmune Llc Andamios multiméricos específicos de TRAIL R2
DK2771022T3 (da) 2011-10-11 2020-09-28 Viela Bio Inc Cd40l-specifikke tn3-afledte skeletter (scaffolds) og fremgangsmåder til anvendelse deraf
MX350202B (es) 2012-03-28 2017-08-30 Amgen Inc Combinaciones de agonistas de receptores de muerte 5 (dr5).
CA2920666A1 (en) 2013-08-12 2015-02-19 Genentech, Inc. Compositions and method for treating complement-associated conditions
WO2015138638A1 (en) 2014-03-11 2015-09-17 Theraly Pharmaceuticals, Inc. Long acting trail receptor agonists for treatment of autoimmune diseases
CR20160561A (es) 2014-05-01 2017-05-03 Genentech Inc Variantes del anticuerpo anti-factor d y sus usos
KR20150133576A (ko) * 2014-05-20 2015-11-30 삼성전자주식회사 화학적 개질된 표적화 단백질 및 그의 이용
US10407510B2 (en) 2015-10-30 2019-09-10 Genentech, Inc. Anti-factor D antibodies and conjugates
US10654932B2 (en) 2015-10-30 2020-05-19 Genentech, Inc. Anti-factor D antibody variant conjugates and uses thereof
JP6797203B2 (ja) 2015-12-17 2020-12-09 ザ・ジョンズ・ホプキンス・ユニバーシティー デスレセプターアゴニストによる全身性硬化症の改善
KR102508650B1 (ko) 2016-04-07 2023-03-13 더 존스 홉킨스 유니버시티 사멸 수용체 작용제로써 췌장암 및 통증을 치료하기 위한 조성물 및 방법
US12344645B2 (en) 2017-03-29 2025-07-01 Polaris Group Protein conjugates
IT201900024622A1 (it) 2019-12-18 2021-06-18 Univ Degli Studi G Dannunzio Chieti Pescara Pegilazione innovativa del killer tnf-apoptosis induced ligand (killer-trail)

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
AU2353384A (en) 1983-01-19 1984-07-26 Genentech Inc. Amplification in eukaryotic host cells
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
GB8430252D0 (en) 1984-11-30 1985-01-09 Beecham Group Plc Compounds
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
DE3779221D1 (de) 1986-08-19 1992-06-25 Genentech Inc Einrichtung und dispersion zum intrapulmonalen eingeben von polypeptidwuchsstoffen und -zytokinen.
ATE105585T1 (de) 1987-12-21 1994-05-15 Univ Toledo Transformation von keimenden pflanzensamen mit hilfe von agrobacterium.
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
DK168302B1 (da) 1989-06-29 1994-03-07 Danisco Fremgangsmåde til indføring af molekyler, især genetisk materiale i planteceller
DE10399023I2 (de) 1989-09-12 2006-11-23 Ahp Mfg B V TFN-bindende Proteine
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
CA2087267A1 (en) 1990-08-17 1992-02-18 Steven H. Bass Metal ion mediated receptor binding of polypeptide hormones
US5206161A (en) 1991-02-01 1993-04-27 Genentech, Inc. Human plasma carboxypeptidase B
AU1757092A (en) 1991-03-28 1992-11-02 Genentech Inc. Stable growth hormone metal ion formulations
AU2147192A (en) 1991-06-28 1993-01-25 Genentech Inc. Method of stimulating immune response using growth hormone
JPH08506095A (ja) 1992-11-25 1996-07-02 アムジェン ボールダー インコーポレイテッド 改変インシュリン様成長因子
EP0708655A1 (en) 1993-04-07 1996-05-01 Amgen Boulder Inc. Methods of using insulin-like growth factor binding proteins
AU685187B2 (en) * 1993-10-29 1998-01-15 Incyte Pharmaceuticals, Inc. Chimeric proteins including protease nexin-1 variants
ES2253753T3 (es) 1995-06-29 2006-06-01 Immunex Corporation Citocina que induce apoptosis.
US6284236B1 (en) * 1995-06-29 2001-09-04 Immunex Corporation Cytokine that induces apoptosis
JP3628333B2 (ja) 1995-09-21 2005-03-09 ジェネンテック インコーポレーテッド ヒト成長ホルモン変異体
US6030945A (en) 1996-01-09 2000-02-29 Genentech, Inc. Apo-2 ligand
EP0939804B2 (en) 1996-10-25 2011-06-15 Human Genome Sciences, Inc. NEUTROKINE alpha
EP2003203A1 (en) 1996-12-23 2008-12-17 Immunex Corporation Ligand for receptor activator of nf-kappa b, ligand is member of TNF superfamily
WO1998032856A1 (en) 1997-01-28 1998-07-30 Human Genome Sciences, Inc. Death domain containing receptor 4 (dr4: death receptor 4), member of the tnf-receptor superfamily and binding to trail (ap02-l)
EP1017794A1 (en) 1997-02-06 2000-07-12 Novo Nordisk A/S Polypeptide-polymer conjugates having added and/or removed attachment groups
US6072047A (en) 1997-02-13 2000-06-06 Immunex Corporation Receptor that binds trail
US20010010924A1 (en) 1997-03-14 2001-08-02 Keith Charles Deen Tumor necrosis factor related receptor, tr6 polynecleotides
ES2281126T3 (es) 1997-03-17 2007-09-16 Human Genome Sciences, Inc. Receptor 5 que contiene un dominio de muerte.
AU7126498A (en) 1997-04-16 1998-11-11 Millennium Pharmaceuticals, Inc. Tumor necrosis factor receptor related proteins tango-63d and tango-63e
ATE363533T1 (de) 1997-04-16 2007-06-15 Amgen Inc Osteoprotegerin bindende proteine und rezeptoren
ATE516354T1 (de) 1997-05-15 2011-07-15 Genentech Inc Apo-2-rezeptor
US6342369B1 (en) 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
AU8400398A (en) 1997-07-11 1999-02-08 Trustees Of The University Of Pennsylvania, The Nucleic acid encoding a novel chemotherapy-induced protein, and methods of use
IL133974A0 (en) 1997-07-14 2001-04-30 Bolder Biotechnology Inc Derivatives of growth hormone and related proteins
US6417328B2 (en) 1997-08-15 2002-07-09 Thomas Jefferson Univeristy Trail receptors, nucleic acids encoding the same, and methods of use thereof
ES2331900T3 (es) 1997-08-26 2010-01-19 Genentech, Inc. Receptor rtd.
AU9376498A (en) 1997-09-05 1999-03-22 University Of Washington Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents
ATE411385T1 (de) 1998-01-15 2008-10-15 Genentech Inc Apo-2 ligand
WO1999037684A1 (en) 1998-01-26 1999-07-29 Genentech, Inc. Antibodies to death receptor 4 (dr4) and uses thereof
PT1192185E (pt) 1999-06-09 2006-11-30 Genentech Inc Sinergismo de agonista do receptor de apo-2l e cpt-11
US6318934B1 (en) * 1999-06-24 2001-11-20 Anchor Wall Systems, Inc. Segmental retaining wall system
ES2392392T3 (es) * 1999-06-28 2012-12-10 Genentech, Inc. Métodos para producir ligando Apo-2 utilizando iones metálicos divalentes
WO2002009755A2 (en) 2000-07-27 2002-02-07 Genentech, Inc. Apo-2l receptor agonist and cpt-11 synergism
CA2461292A1 (en) * 2001-10-02 2003-04-10 Genentech, Inc. Apo-2 ligand variants and uses thereof

Similar Documents

Publication Publication Date Title
JP2010065037A5 (enExample)
JP2010088434A5 (enExample)
JP2010227108A5 (enExample)
JP2011136981A5 (enExample)
JP2009268467A5 (enExample)
JP2011527560A5 (enExample)
JP2010534684A5 (enExample)
JP2010265269A5 (enExample)
JP2013510581A5 (enExample)
JP2014501510A5 (enExample)
JP2020022459A5 (enExample)
JP2012095652A5 (enExample)
JP2011134884A5 (enExample)
JP2011520976A5 (enExample)
JP2010519252A5 (enExample)
JP2012115277A5 (enExample)
JP2007510403A5 (enExample)
JP2009524695A5 (enExample)
JP2011087580A5 (enExample)
JP2013539454A5 (enExample)
JP2007508034A5 (enExample)
JP2006006329A5 (enExample)
JP2009542225A5 (enExample)
JP2014525439A5 (enExample)
JP2012505657A5 (enExample)